ArticleDrugs in context2026
Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use.
Article in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oritavancin is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) with potential applicability across difficult-to-treat Gram-positive infections such as osteomyelitis, bacteraemia and endocarditis. This systematic review evaluates the efficacy, safety and clinical use of oritavancin across on-label and off-label indications. Methods: MEDLINE and CENTRAL were searched (2011-2024) for randomized trials, retrospective cohorts, case series and real-world evidence reporting clinical outcomes following oritavancin administration. Risk of bias was assessed using Critical Appraisal Skills Programme (CASP) tools for randomized clinical trials and cohort studies. Results: Twenty-five studies met inclusion criteria: 11 evaluating ABSSSI ( Conclusions: Oritavancin is effective for ABSSSI and may be a promising treatment alternative for selected Gram-positive off-label indications requiring prolonged therapy. Standardized dosing strategies and prospective trials are needed to define optimal regimens for off-label indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.